Gilead Sciences, Inc. (GILD)
NASDAQ: GILD · Real-Time Price · USD
93.04
+0.08 (0.09%)
At close: Jan 22, 2025, 4:00 PM
93.37
+0.33 (0.35%)
After-hours: Jan 22, 2025, 7:34 PM EST
Gilead Sciences Employees
Gilead Sciences had 18,000 employees as of December 31, 2023. The number of employees increased by 1,000 or 5.88% compared to the previous year.
Employees
18,000
Change (1Y)
1,000
Growth (1Y)
5.88%
Revenue / Employee
$1,572,167
Profits / Employee
$7,000
Market Cap
115.95B
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 18,000 | 1,000 | 5.88% |
Dec 31, 2022 | 17,000 | 2,600 | 18.06% |
Dec 31, 2021 | 14,400 | 800 | 5.88% |
Dec 31, 2020 | 13,600 | 2,600 | 23.64% |
Jan 31, 2019 | 11,000 | 1,000 | 10.00% |
Jan 31, 2018 | 10,000 | 1,000 | 11.11% |
Jan 31, 2017 | 9,000 | 1,000 | 12.50% |
Jan 31, 2016 | 8,000 | 1,000 | 14.29% |
Jan 31, 2015 | 7,000 | 900 | 14.75% |
Jan 31, 2014 | 6,100 | 1,100 | 22.00% |
Jan 31, 2013 | 5,000 | 500 | 11.11% |
Jan 31, 2012 | 4,500 | 500 | 12.50% |
Jan 31, 2011 | 4,000 | 148 | 3.84% |
Jan 31, 2010 | 3,852 | 411 | 11.94% |
Jan 31, 2009 | 3,441 | 462 | 15.51% |
Jan 31, 2008 | 2,979 | 464 | 18.45% |
Jan 31, 2007 | 2,515 | 615 | 32.37% |
Jan 31, 2006 | 1,900 | 246 | 14.87% |
Feb 28, 2005 | 1,654 | 229 | 16.07% |
Feb 27, 2004 | 1,425 | 175 | 14.00% |
Feb 28, 2003 | 1,250 | 250 | 25.00% |
Feb 28, 2002 | 1,000 | 150 | 17.65% |
Feb 28, 2001 | 850 | 90 | 11.84% |
Dec 31, 1999 | 760 | 467 | 159.39% |
Dec 31, 1998 | 293 | 4 | 1.38% |
Dec 31, 1997 | 289 | 41 | 16.53% |
Dec 31, 1996 | 248 | - | - |
Sources: Annual number of employees according to filings submitted to the U.S. Securities and Exchange Commission (SEC). Data is also manually gathered from company press releases, IPO filings, and other official sources.
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 440,000 |
Johnson & Johnson | 131,900 |
Thermo Fisher Scientific | 122,000 |
Abbott Laboratories | 114,000 |
AstraZeneca | 89,900 |
Novartis AG | 76,057 |
Merck & Co. | 72,000 |
Novo Nordisk | 64,319 |
GILD News
- 7 days ago - Gilead Sciences, US government settle patent case over HIV prevention drugs - Reuters
- 9 days ago - Top 5 Cancer Pharma Stocks With Strong Risk/Reward In 2025 - Seeking Alpha
- 9 days ago - Gilead Sciences, Inc. (GILD) JPMorgan Annual Healthcare Conference - (Transcript) - Seeking Alpha
- 9 days ago - Gilead's new HIV prevention drug lenacapavir will ‘change the face of HIV,' says CEO Daniel O'Day - Invezz
- 11 days ago - Gilead, LEO Pharma partner to develop programs for inflammatory diseases - Reuters
- 11 days ago - Gilead and LEO Pharma Enter Into Strategic Partnership to Accelerate Development of Oral STAT6 Program With Potential in Multiple Inflammatory Diseases - Business Wire
- 25 days ago - Gilead Sciences: 2025 Preview, A Buy Thanks To Thriving HIV Franchise - Seeking Alpha
- 4 weeks ago - Gilead Sciences to Present at Upcoming Investor Conference - Business Wire